Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation.

IDR products have major market potential for  infectious disease, cancer, and inflammatory disease.  These products will significantly reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders.  IDR products will also benefit healthcare payors by reducing costs associated with hospitalization.